T-cell co-stimulatory blockade in transplantation: Two steps forward one step back!

Expert Opinion on Biological Therapy

Volumn 13, Issue 11, 2013, Pages 1557-1568

  Riella, Leonardo V ^a   Sayegh, Mohamed H ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Co stimulation; Rejection; Tolerance; Transplantation

Indexed keywords

ABATACEPT; ALEMTUZUMAB; B7 ANTIGEN; BASILIXIMAB; BELATACEPT; CALCINEURIN INHIBITOR; CD28 ANTIGEN; CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MONOCLONAL ANTIBODY CD28; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS; TGN 1412; THYMOCYTE ANTIBODY;

DRUG EFFICACY; DRUG TARGETING; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; LOW DRUG DOSE; MEMORY T LYMPHOCYTE; NEPHROTOXICITY; NONHUMAN; ORGAN TRANSPLANTATION; REGULATORY T LYMPHOCYTE; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TH17 CELL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VASOCONSTRICTION;

ANIMALS; ANTIGENS, CD28; ANTIGENS, CD80; ANTIGENS, CD86; CLINICAL TRIALS AS TOPIC; COSTIMULATORY AND INHIBITORY T-CELL RECEPTORS; CYCLOSPORINE; DISEASE SUSCEPTIBILITY; GRAFT ENHANCEMENT, IMMUNOLOGIC; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOCONJUGATES; IMMUNOLOGIC MEMORY; IMMUNOSUPPRESSIVE AGENTS; INFECTION; KIDNEY DISEASES; LYMPHOCYTE ACTIVATION; LYMPHOPROLIFERATIVE DISORDERS; MOLECULAR TARGETED THERAPY; MULTICENTER STUDIES AS TOPIC; POSTOPERATIVE COMPLICATIONS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; TH17 CELLS; TRANSPLANTATION IMMUNOLOGY;

EID: 84885643356     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.845661     Document Type: Review

References (106)

1. Sayegh MH, Carpenter CB. Transplantation 50 years later-progress, challenges, and promises. N Engl J Med 2004á351(26):2761-6
2. Kahan BD. Cyclosporine. N Engl J Med 1989á321(25):1725-38
3. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003á349(10):931-40
4. Myers BD, Newton L. Cyclosporine-induced chronic nephropathy: An obliterative microvascular renal injury. J Am Soc Nephrol 1991á2(2 Suppl 1): S45-52
5. Pillebout E, Nochy D, Hill G, et al. Renal histopathological lesions after orthotopic liver transplantation (OLT). Am J Transplant 2005á5(5):1120-9
6. Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009á87(2):233-42
7. Sayegh MH, Turka LA. The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med 1998á338(25):1813-21
8. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 2013á 13(4):227-42
9. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996á 14:233-58
10. Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science 1990á 248(4961):1349-56
11. Fraser JD, Irving BA, Crabtree GR, Weiss A. Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28. Science 1991á251(4991):313-16
12. Boise LH, Minn AJ, Noel PJ, et al. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity 1995á 3(1):87-98
13. Howland KC, Ausubel LJ, London CA, Abbas AK. The roles of CD28 and CD40 ligand in T cell activation and tolerance. J Immunol 2000á164(9): 4465-70
14. Khoury SJ, Sayegh MH. The roles of the new negative T cell costimulatory pathways in regulating autoimmunity. Immunity 2004á20(5):529-38
15. Ito T, Ueno T, Clarkson MR, et al. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo. J Immunol 2005á174(11):6648-56
16. Harada H, Salama AD, Sho M, et al. The role of the ICOS-B7h T cell costimulatory pathway in transplantation immunity. J Clin Invest 2003á112(2): 234-43
17. Demirci G, Amanullah F, Kewalaramani R, et al. Critical role of OX40 in CD28 and CD154-independent rejection. J Immunol 2004á172(3):1691-8
18. Keir ME, Liang SC, Guleria I, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 2006á203(4):883-95
19. Li XC, Rothstein DM, Sayegh MH. Costimulatory pathways in transplantation: Challenges and new developments. Immunol Rev 2009á 229(1):271-93
20. Riella LV, Watanabe T, Sage PT, et al. Essential role of PDL1 expression on nonhematopoietic donor cells in acquired tolerance to vascularized cardiac allografts. Am J Transplant 2011á11(4): 832-40
21. Sandner SE, Clarkson MR, Salama AD, et al. Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo. J Immunol 2005á174(6):3408-15
22. Yamada A, Salama AD, Sayegh MH. The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J Am Soc Nephrol 2002á13(2):559-75
23. Yang J, Riella LV, Chock S, et al. The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo. J Immunol 2011á187(3):1113-19
24. Zheng XX, Markees TG, Hancock WW, et al. CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment. J Immunol 1999á162(8): 4983-90
25. Tanaka K, Albin MJ, Yuan X, et al. PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection. J Immunol 2007á179(8):5204-10
26. Riella LV, Paterson AM, Sharpe AH, Chandraker A. Role of the PD-1 pathway in the immune response. Am J Transplant 2012á12(10):2575-87
27. Grohmann U, Orabona C, Fallarino F, et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002á3(11):1097-101
28. Qureshi OS, Zheng Y, Nakamura K, et al. Trans-endocytosis of CD80 and CD86: A molecular basis for the cell-extrinsic function of CTLA-4. Science 2011á332(6029):600-3
29. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a Phase I trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006á355(10): 1018-28
30. Hausen B, Klupp J, Christians U, et al. Coadministration of either cyclosporine or steroids with humanized monoclonal antibodies against CD80 and CD86 successfully prolong allograft survival after life supporting renal transplantation in cynomolgus monkeys. Transplantation 2001á72(6):1128-37
31. Kirk AD, Tadaki DK, Celniker A, et al. Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates. Transplantation 2001á 72(3):377-84
32. Linsley PS, Brady W, Urnes M, et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991á174(3):561-9
33. Turka LA, Linsley PS, Lin H, et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA 1992á89(22):11102-5
34. Lenschow DJ, Zeng Y, Thistlethwaite JR, et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 1992á257(5071): 789-92
35. Levisetti MG, Padrid PA, Szot GL, et al. Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. J Immunol 1997á 159(11):5187-91
36. Kirk AD, Harlan DM, Armstrong NN, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA 1997á94(16):8789-94
37. Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005á5(3):443-53
38. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005á353(8):770-81
39. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A Phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010 10(3):535-46
40. Pestana JO, Grinyo JM, Vanrenterghem Y, et al. Three-year outcomes from BENEFIT-EXT: A phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant 2012á12(3): 630-9
41. Vincenti F, Larsen CP, Alberu J, et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant 2012á12(1):210-17
42. Klintmalm GB FS, Lake JR, et al. Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II study (abstract no. 355). Am J Transplant 2011á 11(Suppl 2):137
43. Adams AB, Williams MA, Jones TR, et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 2003á111(12): 1887-95
44. Braciale TJ, Andrew ME, Braciale VL. Simultaneous expression of H-2-restricted and alloreactive recognition by a cloned line of influenza virus-specific cytotoxic T lymphocytes. J Exp Med 1981á 153(5):1371-6
45. Amir AL, D'Orsogna LJ, Roelen DL, et al. Allo-HLA reactivity of virus-specific memory T cells is common. Blood 2010 115(15):3146-57
46. Wu Z, Bensinger SJ, Zhang J, et al. Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med 2004á10(1):87-92
47. Pearl JP, Parris J, Hale DA, et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005á 5(3):465-74
48. Jameson SC, Masopust D. Diversity in T cell memory: An embarrassment of riches. Immunity 2009á31(6):859-71
49. Valujskikh A, Pantenburg B, Heeger PS. Primed allospecific T cells prevent the effects of costimulatory blockade on prolonged cardiac allograft survival in mice. Am J Transplant 2002á2(6):501-9
50. Kitchens WH, Haridas D, Wagener ME, et al. Integrin antagonists prevent costimulatory blockade-resistant transplant rejection by CD8(+) memory T cells. Am J Transplant 2012á12(1): 69-80
51. Weaver TA, Charafeddine AH, Agarwal A, et al. Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates. Nat Med 2009á15(7):746-9
52. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003á3(3): 199-210
53. Nadig SN, Wieckiewicz J, Wu DC, et al. In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells. Nat Med 2010 16(7):809-13
54. Joffre O, Santolaria T, Calise D, et al. Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes. Nat Med 2008á14(1):88-92
55. Salomon B, Lenschow DJ, Rhee L, et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000á12(4):431-40
56. Tang Q, Henriksen KJ, Boden EK, et al. Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol 2003á171(7):3348-52
57. Riella LV, Liu T, Yang J, et al. Deleterious effect of CTLA4-Ig on a Treg-dependent transplant model. Am J Transplant 2012á12(4):846-55
58. Lechler RI, Garden OA, Turka LA. The complementary roles of deletion and regulation in transplantation tolerance. Nat Rev Immunol 2003á3(2):147-58
59. Semple K, Nguyen A, Yu Y, et al. Strong CD28 costimulation suppresses induction of regulatory T cells from naive precursors through Lck signaling. Blood 2011á117(11):3096-103
60. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998á16:111-35
61. Kawai T, Andrews D, Colvin RB, et al. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 2000á6(2):114
62. Xu H, Zhang X, Mannon RB, Kirk AD. Platelet-derived or soluble CD154 induces vascularized allograft rejection independent of cell-bound CD154. J Clin Invest 2006á116(3):769-74
63. Adams AB, Shirasugi N, Jones TR, et al. Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. J Immunol 2005á 174(1):542-50
64. Aoyagi T, Yamashita K, Suzuki T, et al. A human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys: Induction and maintenance therapy. Am J Transplant 2009á9(8):1732-41
65. Haanstra KG, Ringers J, Sick EA, et al. Prevention of kidney allograft rejection using anti-CD40 and anti-CD86 in primates. Transplantation 2003á 75(5):637-43
66. Haanstra KG, Sick EA, Ringers J, et al. Costimulation blockade followed by a 12-week period of cyclosporine A facilitates prolonged drug-free survival of rhesus monkey kidney allografts. Transplantation 2005á79(11):1623-6
67. Imai A, Suzuki T, Sugitani A, et al. A novel fully human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys. Transplantation 2007á84(8):1020-8
68. Pearson TC, Trambley J, Odom K, et al. Anti-CD40 therapy extends renal allograft survival in rhesus macaques. Transplantation 2002á74(7):933-40
69. Badell IR, Russell MC, Cardona K, et al. CTLA4Ig prevents alloantibody formation following nonhuman primate islet transplantation using the CD40-specific antibody 3A8. Am J Transplant 2012á12(7):1918-23
70. Vu MD, Clarkson MR, Yagita H, et al. Critical, but conditional, role of OX40 in memory T cell-mediated rejection. J Immunol 2006á176(3): 1394-401
71. Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev 2008á 224:166-82
72. Fallarino F, Grohmann U, Hwang KW, et al. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 2003á4(12):1206-12
73. Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995á270(5238) :985-8
74. Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008á322(5899):271-5 PDL.1 interaction as a co-inhibitory pathway in T-cell homeostasis
75. Butte M, Keir M, Phamduy T, et al. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007á27(1):111-33
76. Park JJ, Omiya R, Matsumura Y, et al. B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood 2010 116(8):1291-8
77. Yi T, Li X, Yao S, et al. Host APCs augment in vivo expansion of donor natural regulatory T cells via B7H1/ B7.1 in allogeneic recipients. J Immunol 2011á186(5):2739-49
78. Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17 deficient mice. J Immunol 2003á 171(11):6173-7
79. Tzartos JS, Friese MA, Craner MJ, et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008á 172(1):146-55
80. Burrell BE, Bishop DK. Th17 cells and transplant acceptance. Transplantation 2010 90(9):945-8
81. Antonysamy MA, Fanslow WC, Fu F, et al. Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors. J Immunol 1999á162(1): 577-84
82. Tang JL, Subbotin VM, Antonysamy MA, et al. Interleukin-17 antagonism inhibits acute but not chronic vascular rejection. Transplantation 2001á72(2): 348-50
83. Yuan X, Ansari MJ, D'Addio F, et al. Targeting Tim-1 to overcome resistance to transplantation tolerance mediated by CD8 T17 cells. Proc Natl Acad Sci USA 2009á106(26):10734-9
84. Burrell BE, Csencsits K, Lu G, et al. CD8+ Th17 mediate costimulation blockade-resistant allograft rejection in T-bet-deficient mice. J Immunol 2008á 181(6):3906-14
85. Bouguermouh S, Fortin G, Baba N, et al. CD28 co-stimulation down regulates Th17 development. PLoS One 2009á4(3):e5087
86. Ying H, Yang L, Qiao G, et al. Cutting edge: CTLA-4-B7 interaction suppresses Th17 cell differentiation. J Immunol 2010 185(3):1375-8
87. Grinyo J, Charpentier B, Pestana JM, et al. An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation 2010 90(12):1521-7
88. Dolfi DV, Duttagupta PA, Boesteanu AC, et al. Dendritic cells and CD28 costimulation are required to sustain virus-specific CD8+ T cell responses during the effector phase in vivo. J Immunol 2011á186(8):4599-608
89. Durrbach A, Medina-Pestana JO, Rostaing L, et al. Improving or maintaining renal function with belatacept: 5-year benefit long-term extension results [abstract BO 199]. Oral presentation at the European Society of Organ Transplantationá 2013
90. El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009á9(3) :527-35
91. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012á12(5):1157-67
92. Rostaing L, Massari P, Garcia VD, et al. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: A randomized phase II study. Clin J Am Soc Nephrol 2011á6(2):430-9
93. Lo DJ, Anderson DJ, Weaver TA, et al. Belatacept and sirolimus prolong nonhuman primate renal allograft survival without a requirement for memory T cell depletion. Am J Transplant 2013á13(2):320-8
94. Ferguson R, Grinyo J, Vincenti F, et al. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. Am J Transplant 2011á11(1): 66-76
95. Urakami H, Ostanin DV, Hunig T, Grisham MB. Combination of donor-specific blood transfusion with anti-CD28 antibody synergizes to prolong graft survival in rat liver transplantation. Transplant Proc 2006á38(10):3244-6
96. Azuma H, Isaka Y, Li X, et al. Superagonistic CD28 antibody induces donor-specific tolerance in rat renal allografts. Am J Transplant 2008á8(10): 2004-14
97. Vanhove B, Laflamme G, Coulon F, et al. Selective blockade of CD28 and not CTLA-4 with a single-chain Fv-alpha1-antitrypsin fusion antibody. Blood 2003á102(2):564-70
98. Poirier N, Azimzadeh AM, Zhang T, et al. Inducing CTLA-4-dependent immune regulation by selective CD28 blockade promotes regulatory T cells in organ transplantation. Sci Transl Med 2010 2(17):17ra0
99. Zhang T, Fresnay S, Welty E, et al. Selective CD28 blockade attenuates acute and chronic rejection of murine cardiac allografts in a CTLA-4-dependent manner. Am J Transplant 2011á11(8): 1599-609
100. Poirier N, Mary C, Dilek N, et al. Preclinical efficacy and immunological safety of FR104, an antagonist anti-CD28 monovalent Fab' antibody. Am J Transplant 2012á12(10):2630-40
101. Ashoor I, Najafian N, Korin Y, et al. Standardization and cross validation of alloreactive IFNgamma ELISPOT assays within the clinical trials in organ transplantation consortium. Am J Transplant 2013á13(7):1871-9
102. Hricik DE, Nickerson P, Formica RN, et al. Multicenter validation of urinary CXCL9 as a risk-stratifying biomarker for kidney transplant injury. Am J Transplant 2013á Epub ahead of print
103. Barabasi AL, Gulbahce N, Loscalzo J. Network medicine: A network-based approach to human disease. Nat Rev Genet 2011á12(1):56-68
104. Riella L, Bromberg JS. Literature watch: Implications for transplantation. Am J Transplant 2013á13(1):3
105. Lee MJ, Ye AS, Gardino AK, et al. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 2012á149(4): 780-94
106. Colvin RB. Antibody-mediated renal allograft rejection: Diagnosis and pathogenesis. J Am Soc Nephrol 2007á18(4):1046-56